Update shared on 17 Nov 2025
Fair value Increased 1.97%Narrative Update on Bio-Techne
Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment.
What's in the News
- Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).
- At the 2025 Society for Immunotherapy of Cancer meeting, Bio-Techne and Nucleai presented pivotal clinical trial data that demonstrated how spatial biology and AI-driven biomarker analysis can predict patient response to cancer treatments (Product-Related Announcements).
- The new ProximityScope assay was launched, enabling visualization of protein-protein interactions at subcellular resolution and integrating with Leica Biosystems' BOND RX platform for advanced spatial biology research (Product-Related Announcements).
- Saguaro Biosciences entered a distribution partnership with Bio-Techne, expanding access to high-performance cell-based assay dyes for global researchers (Client Announcements).
- Bio-Techne enhanced its agreement with Oxford Nanopore Technologies by extending collaboration through 2032 to develop advanced genetic screening solutions (Strategic Alliances).
Valuation Changes
- Fair Value: Increased slightly from $67.83 to $69.17, reflecting a positive reassessment of the company’s outlook.
- Discount Rate: Risen from 7.37% to 7.81%, indicating a modest shift in perceived risk or market conditions.
- Revenue Growth: Improved from 5.81% to 6.40%, suggesting higher expectations for top-line expansion.
- Net Profit Margin: Increased from 17.30% to 18.74%, pointing to stronger anticipated profitability.
- Future P/E: Decreased from 48.70x to 47.02x. This signals slightly more favorable valuation multiples for future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.